Biosimilars Deal Might Change The Case For Investing In WuXi Biologics (Cayman) (SEHK:2269)

Simply Wall St.

11/06

Fresenius SE & Co. KGaA recently entered an exclusive development agreement with WuXi Biologics that opens access to up to 37 biosimilar candidates across 13 therapeutic areas, using WuXi ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2681855958"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2681855958\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2681855958?lang=zh_CN&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041","is_english":true,"pubTime":"2026-11-06 16:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681855958","market":"nz","top_or_hot":-1,"title":"Biosimilars Deal Might Change The Case For Investing In WuXi Biologics (Cayman) (SEHK:2269)","media":"Simply Wall St.","content":"<div>\n<p>Fresenius SE &amp; Co. KGaA recently entered an exclusive development agreement with WuXi Biologics that opens access to up to 37 biosimilar candidates across 13 therapeutic areas, using WuXi ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/biosimilars-deal-might-change-the-case-for-investing-in-wuxi\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biosimilars Deal Might Change The Case For Investing In WuXi Biologics (Cayman) (SEHK:2269)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiosimilars Deal Might Change The Case For Investing In WuXi Biologics (Cayman) (SEHK:2269)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-06 16:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/biosimilars-deal-might-change-the-case-for-investing-in-wuxi><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fresenius SE &amp; Co. KGaA recently entered an exclusive development agreement with WuXi Biologics that opens access to up to 37 biosimilar candidates across 13 therapeutic areas, using WuXi ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/biosimilars-deal-might-change-the-case-for-investing-in-wuxi\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0823426480.USD","symbol_name":"法巴中国股票经典Dis","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/biosimilars-deal-might-change-the-case-for-investing-in-wuxi","article_id":"2681855958","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/biosimilars-deal-might-change-the-case-for-investing-in-wuxi","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681855958","pubTimestamp":1793953547,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 6, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0823426480.USD":"法巴中国股票经典Dis","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","BK1589":"北水核心资产","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","BK1521":"挪威政府全球养老基金持仓","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0320764243.SGD":"FTIF - Templeton Emerging Markets A Acc SGD","BK1141":"生命科学工具和服务","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","BK1576":"医药外包概念","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK1610":"ETF&股票定投概念","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","02269":"药明生物","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU0128522744.USD":"TEMPLETON EMERGING MARKETS \"A\" ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0229945570.USD":"TEMPLETON BRIC \"A\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0708995153.HKD":"TEMPLETON EMERGING MARKETS \"A\" (HKD) ACC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0823426308.USD":"法巴中国股票基金","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","SG9999011746.SGD":"PINEBRIDGE INTERNATIONAL FUNDS - ACORNS OF ASIA BA (SGD) ACC"},"translate_title":"生物仿制药交易可能会改变投资药明生物（开曼）（SEHK:2269）的情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":0.9,"KURE":0.6},"content_text":"Fresenius SE &amp; Co. KGaA recently entered an exclusive development agreement with WuXi Biologics that opens access to up to 37 biosimilar candidates across 13 therapeutic areas, using WuXi Biologics' global CRDMO network for research, development and manufacturing. The deal positions WuXi Biologics at the center of what Fresenius describes as the largest biosimilars development agreement so far, tying WuXi Biologics’ capacity and complex modality know how directly to a long runway of potential late stage and commercial work. We will examine how WuXi Biologics' investment narrative is shaped by this large scale Fresenius biosimilars development pipeline expansion.  Scan the biosimilars space beyond WuXi Biologics (Cayman) by reviewing a curated group of 125 healthcare AI stocks aligned with advanced biologic and AI driven drug development. AdvertisementWuXi Biologics (Cayman) Investment Narrative Recap To own WuXi Biologics (Cayman), you need to believe its integrated CRDMO model in complex biologics can keep attracting projects and converting them into long duration manufacturing work and IP linked revenue. The Fresenius agreement points in that direction, since it ties WuXi Biologics’ network to a large, clearly defined biosimilar funnel that could support capacity utilization. The near term watchpoint is still execution on existing late stage programs and any fallout from geopolitical or legislative risk, especially around US exposure. This Fresenius deal does not remove those pressures, although it may soften client concentration risk if programs scale as planned over time. The ESG awards in Hong Kong matter more than they might look at first glance. WuXi Biologics was recognized for Best ESG Report and Excellence in Environmental Positive Impact, which lines up with management’s Green CRDMO messaging and its push into more efficient single use and digital twin enabled facilities. Regarding potential catalysts, this recognition supports the idea that large pharma and biopharma clients may view WuXi Biologics as a lower risk long term outsourcing partner, particularly in regulated markets that scrutinize supply chain emissions and disclosures. The operational flip side is that any gap between ESG commitments and actual execution could quickly become a reputational risk. WuXi Biologics (Cayman)'s current analyst narrative points to CN¥38.3b in revenue and CN¥9.2b in earnings by 2029, based on an assumed 17.4% yearly revenue growth rate and an earnings increase of roughly CN¥4.2b from the CN¥5.0b reported today. Uncover why WuXi Biologics (Cayman)'s fair value indicates a 24% potential upside to its current price, which could narrow quickly. SEHK:2269 1-Year Stock Price Chart Exploring Other Perspectives One alternate view focuses on the biosimilar ramp itself. Some of the most optimistic analysts already modeled WuXi Biologics reaching CN¥45.6b in revenue and CN¥11.3b in earnings by 2029 before this Fresenius deal. You can see how this fresh pipeline access could push those upbeat scenarios even higher or force a rethink. Explore another WuXi Biologics (Cayman) fair value estimate, including one that suggests upside of as much as 102% from the current price! Reach Your Own Conclusion Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own analysis carefully.  A great starting point for your WuXi Biologics (Cayman) research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. See our latest analysis for WuXi Biologics (Cayman). The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easier to review WuXi Biologics (Cayman)'s overall financial profile at a glance.  Looking For More Investment Ideas Beyond WuXi Biologics? If WuXi Biologics (Cayman) has you rethinking how you build exposure to healthcare, it can help to line it up against other opportunities that fit different risk and income profiles using the Simply Wall St Screener.  For investors who focus on quality at a discount, check out a 224 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect them yet. If stability and balance sheet strength sit high on your checklist, scan a list of solid balance sheet and fundamentals (193 results) that can help anchor a more resilient portfolio. When you want to uncover fresh ideas off the beaten path, review a 592 high quality undiscovered gems that pair robust financials with relatively low market attention.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if WuXi Biologics (Cayman) might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}